Cynthia Gail Leichman

Summary

Affiliation: St. Vincent's Comprehensive Cancer Center
Country: USA

Publications

  1. ncbi Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study
    Cynthia G Leichman
    Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA 92262, USA
    Clin Colorectal Cancer 5:119-23. 2005
  2. ncbi Adjuvant therapy for colon cancer 2005: new options in the twenty-first century
    Cynthia Gail Leichman
    Comprehensive Cancer Center at Desert Regional Medical Center, 1180 N Indian Canyon Drive E218, Palm Springs, CA 92262, USA
    Surg Oncol Clin N Am 15:159-73. 2006
  3. ncbi Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future
    Lawrence Leichman
    Clinical Genomics, Comprehensive Cancer Centers of the Desert, Salick Health Care, Inc, Palm Springs, CA 92262, USA
    Semin Oncol 30:11-8. 2003
  4. ncbi Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer
    Nikhil I Khushalani
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 20:2844-50. 2002
  5. ncbi Regional chemotherapy is indicated after surgical resection of colorectal metastases to the liver: a debate
    Nikhil I Khushalani
    Division of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Surg Oncol 82:65-72. 2003

Collaborators

Detail Information

Publications5

  1. ncbi Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study
    Cynthia G Leichman
    Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA 92262, USA
    Clin Colorectal Cancer 5:119-23. 2005
    ..A companion trial was funded to assess molecular parameters associated with fluoropyrimidine response or resistance and toxicity from these treatments...
  2. ncbi Adjuvant therapy for colon cancer 2005: new options in the twenty-first century
    Cynthia Gail Leichman
    Comprehensive Cancer Center at Desert Regional Medical Center, 1180 N Indian Canyon Drive E218, Palm Springs, CA 92262, USA
    Surg Oncol Clin N Am 15:159-73. 2006
    ..The addition of irinotecan to 5-FU and LV regimens has not demonstrated an advantage compared with 5-FU/LV treatments in the adjuvant setting...
  3. ncbi Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future
    Lawrence Leichman
    Clinical Genomics, Comprehensive Cancer Centers of the Desert, Salick Health Care, Inc, Palm Springs, CA 92262, USA
    Semin Oncol 30:11-8. 2003
    ..A secondary endpoint of the study was the relationship between efficacy and toxicity to specific intratumoral gene expressions within the primary esophageal tumor...
  4. ncbi Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer
    Nikhil I Khushalani
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 20:2844-50. 2002
    ..CONCLUSION: OXP 85 mg/m(2) on days 1, 15, and 29 administered with PI 5-FU and XRT is safe, tolerable, and seems effective against primary EC. The role of OXP in multimodality regimens against EC deserves further evaluation...
  5. ncbi Regional chemotherapy is indicated after surgical resection of colorectal metastases to the liver: a debate
    Nikhil I Khushalani
    Division of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Surg Oncol 82:65-72. 2003
    ..They appear as Parts 1 and 2 in this article. This exercise is purely educational and does not in any way reflect the opinion or the clinical practice of the authors. ...